iRhythm Technologies Inc. recently presented at the William Blair 45th Annual Growth Stock Conference, highlighting the capabilities of their Zio platform. The company reported a first-quarter 2025 revenue of $158.7 million, marking a 20.3% increase compared to the same period in 2024. iRhythm's patented wearable biosensors, combined with a second-generation, FDA-cleared AI platform, provide a scalable digital solution for cardiac monitoring. The company has posted over 10 million patient reports and curated more than 2.5 billion hours of ECG data since its inception. With over 30% penetration in the U.S. ambulatory cardiac monitoring market and a target market opportunity in prioritized EU and APAC countries, iRhythm aims to address the growing burden of cardiac arrhythmias. You can access the full presentation through the link below.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.